| RSS
Business center
Office
Post trade leads
Post
Rank promotion
Ranking
 
You are at: Home » News » International »

Competition in the RMB3 Billion Psoriasis Drug Market Turning White-hot!

Increase font size  Decrease font size Date:2019-07-11   Views:18

J & J’s guselkumab (trade name: Tremfya) has recently been applied for marketing in China, which is called the “best psoriasis drug” owing to its separately defeating adalimumab and secukinumab in the head-to-head studies, with sales reaching USD544 million in 2018, showing the potential of becoming a blockbuster.

 
 
[ Search ]  [ ]  [ Email ]  [ Print ]  [ Close ]  [ Top ]

 
Total:0comment(s) [View All]  Related comment

 
Recomment
Popular
 
 
Home | About | Service | copyright | agreement | contact | about | SiteMap | Links | GuestBook | Ads service | 京ICP 68975478-1
Tel:+86-10-68645975           Fax:+86-10-68645973
E-mail:yaoshang68@163.com     QQ:1483838028